Janus Henderson Global Life Sciences Fund Q2 2024 Commentary

seekingalpha09-20

Janus Henderson Global Life Sciences Fund returned 1.95% and the MSCI World Health Care IndexSM returned 0.48%.Stock selection in healthcare equipment contributed to relative returns, while ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468621318?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425769187/image_1425769187.jpg","is_english":true,"pubTime":"2024-09-20 22:10","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2468621318","market":"sh","top_or_hot":-1,"title":"Janus Henderson Global Life Sciences Fund Q2 2024 Commentary","media":"seekingalpha","content":"<div>\n<p>Janus Henderson Global Life Sciences Fund returned 1.95% and the  MSCI World Health Care IndexSM returned 0.48%.Stock selection in healthcare  equipment contributed to relative  returns, while ...</p>\n\n<a href=\"https://seekingalpha.com/article/4722324-janus-henderson-global-life-sciences-fund-q2-2024-commentary\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janus Henderson Global Life Sciences Fund Q2 2024 Commentary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanus Henderson Global Life Sciences Fund Q2 2024 Commentary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-20 22:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4722324-janus-henderson-global-life-sciences-fund-q2-2024-commentary><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Janus Henderson Global Life Sciences Fund returned 1.95% and the  MSCI World Health Care IndexSM returned 0.48%.Stock selection in healthcare  equipment contributed to relative  returns, while ...</p>\n\n<a href=\"https://seekingalpha.com/article/4722324-janus-henderson-global-life-sciences-fund-q2-2024-commentary\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066053197.SGD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","start_time":0,"source_url":"https://seekingalpha.com/article/4722324-janus-henderson-global-life-sciences-fund-q2-2024-commentary","article_id":"2468621318","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425769187/image_1425769187.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468621318","pubTimestamp":1726841400,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Click to enlarge  Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance call 800.668.0434 or visit Products - US Advisor. Maximum Offering Price  returns include the maximum sales charge of 5.75%. Net Asset Value  returns exclude this charge, which would have reduced returns. Expense Ratios  Class I: Gross 0.77, Net 0.77 Class T: Gross 0.92, Net 0.92 Class N: Gross 0.67, Net 0.67 Class A: Gross 0.98, Net 0.98 Not all Funds and Share classes may be available. Please consult your financial professional. Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance call 800.668.0434 or visit Pr","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0882574055.USD":"富达全球健康医疗A ACC","SNY":"赛诺菲安万特","BSX":"波士顿科学","INSM":"Insmed","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","SRPT":"Sarepta Therapeutics","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","NVO":"诺和诺德","BK4568":"美国抗疫概念","NAV":"纳威司达","VRTX":"福泰制药","GMED":"Globus Medical Inc","AVDL":"Avadel Pharmaceuticals plc","LU0097036916.USD":"贝莱德美国增长A2 USD","LLY":"礼来","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","ABBV":"艾伯维公司","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","JNJ":"强生","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","UTHR":"美国联合医疗","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","MRK":"默沙东","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4516":"特朗普概念","NVS":"诺华","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","AZN":"阿斯利康","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","FDMT":"4D Molecular Therapeutics","BK4567":"ESG概念","ETNB":"89Bio, Inc.","BK4585":"ETF&股票定投概念","AMGN":"安进","ASND":"Ascendis Pharma A/S","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","BK4566":"资本集团"},"translate_title":"骏利亨德森全球生命科学基金2024年第二季度评论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"VRTX":1,"UTHR":1,"SRPT":1,"SNY":1,"NVS":1,"NVO":1,"NAV":1,"MRK":1,"JNJ":1,"INSM":1,"GMED":1,"FDMT":1,"ABBV":1,"BSX":1,"ASND":1,"AVDL":1,"AZN":1,"BHVN":1,"ETNB":1,"LLY":0.9},"content_text":"Janus Henderson Global Life Sciences Fund returned 1.95% and the  MSCI World Health Care IndexSM returned 0.48%.Stock selection in healthcare  equipment contributed to relative  returns, while positioning in  biotechnology weighed on  performance.Attractive valuations, accelerating  innovation, and mergers and  acquisitions continue to be tailwinds  for the healthcare sector.ipopba Global Life Sciences Fund Performance - USD (%) (as of 06/30/24)     Cumulative     Annualized         Returns 2Q24 YTD 1 Yr 3 Yr 5 Yr 10 Yr  Since Inception (12/31/98)    Class I Shares (MUTF:JFNIX) 1.95 10.68 15.17 5.90 11.55 11.24 11.55   Class T Shares (MUTF:JAGLX) 1.90 10.59 15.01 5.75 11.39 11.09 11.46   Class N Shares (MUTF:JFNNX) 1.96 10.73 15.27 5.99 11.65 11.25 11.52   Class A Shares (MUTF:JFNAX) @ NAV 1.88 10.56 14.91 5.66 11.31 10.99 11.33   Class A Shares @ MOP -3.97 4.20 8.30 3.60 10.00 10.34 11.08   MSCI World Health Care Index SM 0.48 7.99 11.17 4.92 10.10 8.73 6.91   S&P 500® Index (SP500, SPX) 4.28 15.29 24.56 10.01 15.04 12.86 8.01  \nClick to enlarge  Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance call 800.668.0434 or visit Products - US Advisor. Maximum Offering Price (MOP) returns include the maximum sales charge of 5.75%. Net Asset Value (NAV) returns exclude this charge, which would have reduced returns. Expense Ratios (% as of most recent prospectus) Class I: Gross 0.77, Net 0.77 Class T: Gross 0.92, Net 0.92 Class N: Gross 0.67, Net 0.67 Class A: Gross 0.98, Net 0.98 Not all Funds and Share classes may be available. Please consult your financial professional. Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance call 800.668.0434 or visit Products - US Advisor. \nClick to enlarge  Investment environment Healthcare stocks finished positive for the quarter but underperformed the broader equity market. Pharmaceuticals led the sector, thanks in part to growing demand for GLP-1 obesity and diabetes drugs. Positive clinical trial readouts in large markets, such as oncology, were another tailwind. Biotechnology stocks also gained. Although merger and acquisition (M&A) activity slowed, deals continued in growth areas such as radiopharmaceuticals, including Novartis' (NVS) acquisition of Mariana Oncology. The medical device/technology subsectors lagged on concerns that pent-up demand from COVID-19 could wane in the second half of 2024. Some firms also lowered sales guidance. Portfolio review For the second quarter in a row, Sarepta Therapeutics (SRPT) was a top contributor. We have been long-term holders of the company, a leader in the field of Duchenne muscular dystrophy (DMD). Last year, Sarepta received accelerated approval for its breakthrough gene therapy, Elevidys, but the drug was limited to 4- and 5-year-olds who could walk. In June, the Food and Drug Administration (FDA) expanded approval to all DMD patients aged 4 and older. DMD is a severe type of muscular dystrophy that leads to rapid muscle weakness; patients often end up in wheelchairs in their teens and have a life expectancy in their 20s. Given the high unmet need and the expanded label, Elevidys should see rapidly accelerating sales in the coming months. Insmed (INSM) was another top contributor. During the quarter, the company reported positive phase 3 results for brensocatib for bronchiectasis, a lung disease affecting one million individuals globally (with millions more likely undiagnosed). Bronchiectasis causes the airways to become widened and thickened from inflammation, leading to respiratory infections and chronic cough. With no approved treatments for the condition, we believe brensocatib has blockbuster potential (annual sales of $1 billion or more). Other holdings weighed on performance, including Biohaven (BHVN). The stock declined after the company reported phase 1 data for BHV-1300, an experimental protein degrader to treat immune-related disorders. Although the drug delivered positive results - reducing autoantibody IgG levels with no severe side effects - the early data fell short of expectations. We think investors set their sights too high for this dose- ranging study. More importantly, BHV-1300's clean safety profile is encouraging for Biohaven's broader MoDE platform (molecular degraders of extracellular proteins), which could potentially treat a variety of autoimmune diseases. Another detractor was 4D Molecular Therapeutics (FDMT). The firm is developing a range of gene therapies that use a platform of customized delivery vehicles (vectors) to shuttle genes into appropriate cells. However, after rallying earlier in the year, the stock pulled back after 4D reported inconclusive data for its drug aimed at cystic fibrosis lung disease. 4D's pipeline also includes a program for retinal disease, which is being closely watched for safety and durability (i.e., reducing the need for eye injections) as trials expand to a broader patient population. Manager outlook Although healthcare has trailed the AI-driven rally of the broader equity market so far in 2024, the sector still delivered solid gains in the first half of the year. New product launches, attractive valuations, ongoing innovation, and strong demand for medical care have helped lift stocks. But returns have also been uneven, underscoring that fundamentals matter in healthcare. In pharmaceuticals, for example, sales of GLP-1s are now annualizing more than $40 billion and growing over 30% per year, benefiting the leading makers of these novel weight- loss and diabetes medicines. However, other pharma companies face headwinds from patent expirations and lackluster R&D pipelines. In medical devices, some stocks have enjoyed double-digit gains this year thanks to innovation in areas such as robotic surgery and atrial fibrillation therapy. But those lacking new products have lagged due to concerns that a surge in demand for routine medical care post-COVID could be peaking. It is a good reminder that healthcare can experience wide dispersions of returns and why we believe a selective approach is warranted to best capitalize on the sector's long- term growth opportunities. In our portfolio, we remain overweight small- and mid-cap biotechs with newly launching products or late-stage pipelines. These companies increasingly stand out for their ability to raise capital and become acquisition targets, especially in exciting growth areas such as antibody-drug conjugates, radiopharmaceuticals, and cell and gene therapies. We also favor pharma companies with improving visibility around their R&D pipelines and medical device makers with new product launches. At the same time, healthcare continues to offer defensive qualities that could appeal to investors should tight financial conditions cause the economy to slow in the months ahead. As such, we favor biopharma companies with strong balance sheets, as well as health insurers. The managed care industry has underperformed this year on rising costs, but that could change if medical utilization moderates, as some data indicate. Insurers can also reprice services annually, which we think adds to their long-term outlook. In summary, we believe healthcare offers long-term growth potential from innovation in biopharma and medical devices, along with the ability to weather an uncertain economic outlook through attractive valuations and defensive characteristics - a winning combination, in our view. Portfolio   Top Contributors (%) Average Weight Relative Contribution Top Detractors (%) Average Weight Relative Contribution   Sarepta Therapeutics In 1.81 0.36 Biohaven Ltd 0.87 -0.43   Insmed Inc 0.32 0.35 4d Molecular Therapeuti 0.50 -0.21   Johnson & Johnson (JNJ) 0.66 0.31 89bio Inc (ETNB) 0.52 -0.21   United Therapeutics (UTHR) 0.93 0.25 Avadel Pharmaceuticals (AVDL) 0.90 -0.16   Globus Med Inc (GMED) 1.00 0.24 Ascendis Pharma A S (ASND) 1.31 -0.15  \nClick to enlarge  The holdings identified in this table, in compliance with Janus Henderson policy, do not represent all of the securities purchased, held or sold during the period. To obtain a list showing every holding as a percentage of the portfolio at the end of the most recent publicly available disclosure period, contact 800.668.0434 or visit Products - US Advisor. Relative contribution reflects how the portfolio's holdings impacted return relative to the benchmark. Cash and securities not held in the portfolio are not shown. \nClick to enlarge   Top Holdings (%) Fund   Eli Lilly & Co (LLY) 9.37   UnitedHealth Group Inc 6.15   Novo Nordisk A/S (NVO) 5.96   AstraZeneca PLC (AZN) 3.78   AbbVie Inc (ABBV) 3.69   Merck & Co Inc (MRK) 3.29   Amgen Inc (AMGN) 3.11   Sanofi SA (SNY) 2.46   Boston Scientific Corp (BSX) 2.43   Vertex Pharmaceuticals Inc (VRTX) 2.36   Total 42.60  \nClick to enlarge   Please consider the charges, risks, expenses and investment objectives carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, please call Janus Henderson at 800.668.0434 or download the file from Products - US Advisor. Read it carefully before you invest or send money. Performance for Class A and I Shares that includes periods prior to 7/6/09 reflects the performance of one or more share classes of the Fund or a predecessor fund, adjusted, where applicable and permitted, for differing fees and expenses. See the Fund's prospectus for further details. Performance for Class N Shares that includes periods prior to 1/26/18 reflects the performance of one or more share classes of the Fund or a predecessor fund, adjusted, where applicable and permitted, for differing fees and expenses. See the Fund's prospectus for further details. Returns include reinvestment of dividends and capital gains. Discussion is based on the performance of Class I Shares. The opinions are as of 06/30/24, are subject to change and may not reflect the views of others in the organization. Janus Henderson may have a business relationship with certain entities discussed. The comments should not be construed as a recommendation of individual holdings or market sectors, but as an illustration of broader themes. Holdings are subject to change without notice. For equity portfolios, relative contribution compares the performance of a security in the portfolio to the benchmark's total return, factoring in the difference in weight of that security in the benchmark. Returns are calculated using daily returns and previous day ending weights rolled up by ticker, gross of advisory fees, may exclude certain derivatives and does not represent actual performance. There is no assurance the stated objective(s) will be met. Investing involves risk, including the possible loss of principal and fluctuation of value. Foreign securities are subject to additional risks including currency fluctuations, political and economic uncertainty, increased volatility, lower liquidity and differing financial and information reporting standards, all of which are magnified in emerging markets. Concentrated investments in a single sector, industry or region will be more susceptible to factors affecting that group and may be more volatile than less concentrated investments or the market as a whole. Smaller capitalization securities may be less stable and more susceptible to adverse developments, and may be more volatile and less liquid than larger capitalization securities. Growth stocks are subject to increased risk of loss and price volatility and may not realize their perceived growth potential. Initial Public Offerings ('IPOs') are highly speculative investments and may be subject to lower liquidity and greater volatility. Special risks associated with IPOs include limited operating history, unseasoned trading, high turnover and non-repeatable performance. Environmental, Social and Governance ('ESG') or sustainable investing considers factors beyond traditional financial analysis. This may limit available investments and cause performance and exposures to differ from, and potentially be more concentrated in certain areas than, the broader market. Actively managed investment portfolios are subject to the risk that the investment strategies and research process employed may fail to produce the intended results. Accordingly, a portfolio may underperform its benchmark index or other investment products with similar investment objectives. MSCI World Health Care Index℠ reflects the performance of health care stocks from global developed markets. S&P 500® Index reflects U.S. large-cap equity performance and represents broad U.S. equity market performance. Index performance does not reflect the expenses of managing a portfolio as an index is unmanaged and not available for direct investment. Mutual funds distributed by Janus Henderson Distributors US LLC. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc. 188-42-16676 07-24 10-15-24 \nClick to enlarge  Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"analysis","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468621318"}